The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial
Shojaei F, Erfanifar A, Kalbasi S, et al.
BMC Endocr Disord. 2025;25(1):52.
Leggi
Shojaei F, Erfanifar A, Kalbasi S, et al.
BMC Endocr Disord. 2025;25(1):52.
Leggi
Cunningham JW, Chatur S, Claggett BL, et al.
JAMA Cardiol. 2025:e250016.
Leggi
Ostrominski JW, Claggett BL, Miao ZM, et al.
Diabetes Care. 2025:dc241873.
Leggi
Tang H, Lu Y, Donahoo WT, et al.
Ann Intern Med. Pub. online 25 Feb 2025.
Leggi
Pang X, Dan W, Lin L
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Shen L, Zhang S, Wen J, et al.
BMC Pregnancy Childbirth. 2025;25(1):203.
Leggi
Berry SA, Liarakos AL, Koutroukas V, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Goshrani A, Lin R, O’Neal D, Ekinci EI
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Olsen MT, Jensen SH, Rasmussen LM, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Roberts CGP, Athinarayanan SJ, Ratner RE, Umpierrez GE
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi